Literature DB >> 32451690

Gastric cancer in young patients: a separate entity with aggressive features and poor prognosis.

Lyujia Cheng1,2, Songyao Chen1,2, Wenhui Wu1, Zi Chong Kuo1, Zhewei Wei2, Sijun Meng1, Chuangqi Chen2, Changhua Zhang3, Yulong He4,5.   

Abstract

PURPOSE: To investigate the clinicopathological features and survival outcomes between young and old patients with gastric cancer (GC), and further determine the role of young age in the prognosis of GC.
METHODS: Patients with stage I-III gastric adenocarcinomas undergoing curative surgery were enrolled, divided into young (aged 18-49 years, YG), middle-aged (50-59 years, MG), and old (≥ 60 years, OG) groups. Exclusion criteria were neoadjuvant therapy and history of malignant tumors. Clinicopathological features, overall survival (OS), disease-free survival (DFS), and recurrence patterns were compared among three groups.
RESULTS: 1131 patients were finally included, with 270, 314, and 547 cases in the YG, MG, and OG, respectively. Compared to others, YG had higher proportion of female, middle-third gastric cancer, poor differentiation, N3b stage, and adjuvant chemotherapy. YG demonstrated poorer 5-year OS than MG (62.4% vs. 70.8%, P = 0.019), but better than OG (62.4% vs. 58.7%, P = 0.031). YG also suffered inferior 5-year DFS (75.2% vs. 82.8%, P = 0.040) compared with MG, and higher incidence of peritoneal recurrence than MG (15.1% vs. 5.2%, P < 0.001) and OG (15.1% vs. 4.1%, P < 0.001). Multivariate analysis identified young age as the independent prognostic factor for OS [hazard ratio (HR) = 1.347, 95% CI 1.018-1.781, P = 0.037], DFS (HR = 1.601, 95% CI 1.079-2.376, P = 0.019), and peritoneal recurrence (HR = 2.936, 95% CI 1.505-5.726, P = 0.002).
CONCLUSIONS: Young GC patients demonstrated aggressive features with poor prognosis and enhanced management may be warranted for this subgroup.

Entities:  

Keywords:  Gastric cancer; Peritoneal recurrence; Prognosis; Recurrence pattern; Young

Year:  2020        PMID: 32451690     DOI: 10.1007/s00432-020-03268-w

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  6 in total

1.  Outcomes of adolescent and young patients with hepatocellular carcinoma after curative liver resection: a retrospective study.

Authors:  Zheng-Yun Zhang; Jiao Guan; Xin-Ping Wang; Di-Si Hao; Zun-Qiang Zhou
Journal:  World J Surg Oncol       Date:  2022-06-21       Impact factor: 3.253

2.  Long-term oncological prognosis after curative-intent liver resection for hepatocellular carcinoma in the young versus the elderly: multicentre propensity score-matching study.

Authors:  Jia-Le Pu; Zhong Chen; Lan-Qing Yao; Ji-Ye Feng; Yong-Kang Diao; Ming-Cheng Guan; Ju-Dong Li; Zheng-Liang Chen; Ya-Hao Zhou; Hong Wang; Wei-Min Gu; Jie Li; Chao Li; Ming-Da Wang; Hong Zhu; Ying-Jian Liang; Feng Shen; Timothy M Pawlik; Wan Yee Lau; Tian Yang
Journal:  BJS Open       Date:  2022-01-06

3.  Long noncoding RNA NR2F1-AS1 plays a carcinogenic role in gastric cancer by recruiting transcriptional factor SPI1 to upregulate ST8SIA1 expression.

Authors:  Fang Zuo; Yong Zhang; Jianting Li; Shaoxiang Yang; Xiaolu Chen
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

4.  A Distinct Clinicopathological Feature and Prognosis of Young Gastric Cancer Patients Aged ≤ 45 Years Old.

Authors:  Qian Huang; Xiufeng Zheng; Yang Jiao; Yanna Lei; Xiaoying Li; Feng Bi; Fukun Guo; Gang Wang; Ming Liu
Journal:  Front Oncol       Date:  2021-08-26       Impact factor: 6.244

5.  Somatic Alteration Characteristics of Early-Onset Gastric Cancer.

Authors:  Qiyang Zhou; Feng Tao; Liqing Qiu; Hanlin Chen; Hua Bao; Xue Wu; Yang Shao; Liangjie Chi; Hu Song
Journal:  J Oncol       Date:  2022-04-22       Impact factor: 4.501

6.  hsa_circ_0060975 is highly expressed and predicts a poor prognosis in gastric cancer.

Authors:  Peng Xu; Xiaolan Xu; Lixiang Zhang; Zhengnan Li; Jianjun Qiang; Jie Yao; Aman Xu
Journal:  Oncol Lett       Date:  2021-06-24       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.